Oxford/AstraZeneca vaccine offers limited protection against mild disease caused by COVID-19 variant

Oxford/AstraZeneca COVID-19 vaccine offers limited protection against South African variant

Analysis submitted as a pre-print prior to peer-review publication has shown that a two-dose regimen of the Oxford/AstraZeneca COVID-19 vaccine provides minimal protection against...
One dose of Oxford/AstraZeneca COVID-19 vaccine could provide sustained

One dose of Oxford/AstraZeneca COVID-19 vaccine could provide sustained protection

Researchers at the University of Oxford have published in Preprints with The Lancet an analysis of further data from the ongoing trials of the Oxford coronavirus...
Sputnik V COVID-19 vaccine demonstrates 91.6% efficacy

Sputnik V COVID-19 vaccine demonstrates 91.6% efficacy

The Lancet has published interim results of a Phase III clinical trial of Sputnik V, confirming the vaccine demonstrated efficacy of 91.6%. Sputnik V,...
EU authorisation for AstraZeneca’s COVID-19 vaccine

EU authorisation for AstraZeneca’s COVID-19 vaccine

AstraZeneca’s COVID-19 vaccine has been recommended for conditional marketing authorisation (CMA) in the European Union (EU) for active immunisation to prevent COVID-19 in individuals...
Additional 4 million doses of Valneva COVID-19 vaccine for UK

Additional 4 million doses of Valneva COVID-19 vaccine for UK

Valneva, a specialty vaccine company focused on prevention against diseases with major unmet needs, has reported that the UK Government has ordered 40 million...
Increased footfall in pharmacies: Making the most of it

Increased footfall in pharmacies: Making the most of it

Involving pharmacists in the UK’s Covid-19 vaccine roll out programme not only recognises their importance, but also presents an opportunity to reignite conversations around...
The cost of COVID-19 on lung cancer progress

The cost of COVID-19 on lung cancer progress

Lung cancer is the largest cause of cancer deaths in the world and there is no doubt that the COVID-19 pandemic has had a...
Novavax COVID-19 vaccine demonstrates 89.3% efficacy in UK trial

Novavax COVID-19 vaccine demonstrates 89.3% efficacy in UK trial

Novavax has announced that its protein-based COVID-19 vaccine candidate has an efficacy of 89.3%, following results from its Phase III clinical trial conducted in...
UK COVID-19 death rate reaches 100,000

UK COVID-19 death rate reaches 100,000

Latest figures from the Office for National Statistics (ONS) shows the total number of deaths in the UK involving COVID-19 is now more than...
Merck discontinues development of its two COVID-19 vaccines

MSD discontinues development of its COVID-19 vaccines

MSD has announced that the company is discontinuing development of its two COVID-19 vaccine candidates, V590 and V591, following a review of findings from...

Latest articles

Antibiotic Research UK launches small research grants programme

Antibiotic Research UK launches small research grants programme

Antibiotic Research UK (ANTRUK), the world’s first charity tackling bacterial antibiotic resistance, has just launched its largest grants programme to date, the 2021 Small...
First AI-designed Immuno-oncology drug to enter clinical trials

First AI-designed Immuno-Oncology drug to enter clinical trials

Discovered within 8 months of project initiation, the first AI-designed molecule for Immuno-Oncology is to enter human clinical trials. The A2a receptor antagonist, which is in development...
ViiV Healthcare's long-acting injectable HIV treatment authorised in EU

The first self-administered B-cell therapy for patients with relapsing forms of MS

Novartis receives European and UK licence for Kesimpta®▼(ofatumumab) Ofatumumab is a self-administered targeted B-cell depleting treatment option for adult patients living with relapsing forms of...

Popular articles

Image of a person descending a ladder over coronavirus to show New Normal, New Thinking: Life Post COVID-19

New Normal, New Thinking: Life Post COVID-19

New thinking will be required to adapt to the new normal life post COVID-19. I hate to start this article on a negative note, but...
Image of a scientist at their lab to show Study shows existing anti-parasitic drug kills coronavirus within 48 hours

Study shows anti-parasitic drug ivermectin kills coronavirus within 48 hours

A collaborative study led by the Monash Biomedicine Discovery Institute (BDI) with the Peter Doherty Institute of Infection and Immunity (Doherty Institute), a joint...
ViiV Healthcare's long-acting injectable HIV treatment authorised in EU

The first self-administered B-cell therapy for patients with relapsing forms of MS

Novartis receives European and UK licence for Kesimpta®▼(ofatumumab) Ofatumumab is a self-administered targeted B-cell depleting treatment option for adult patients living with relapsing forms of...
New COVID-19 test reduces testing time from 30 minutes to five

New COVID-19 test reduces testing time from 30 minutes to five

University of Birmingham researchers have invented a COVID-19 test that reduces testing time from 30 minutes to under five, whilst still delivering accurate results. The...
First AI-designed Immuno-oncology drug to enter clinical trials

First AI-designed Immuno-Oncology drug to enter clinical trials

Discovered within 8 months of project initiation, the first AI-designed molecule for Immuno-Oncology is to enter human clinical trials. The A2a receptor antagonist, which is in development...

Subscribe

Sign up to receive your free UK subscription to Pf Magazine and our digital newsletters, for all the essential headlines, Jobs of the Week, and thought-provoking features.

Claim my free subscription